Vaccine:新措施有效改善青少年HPV疫苗接种率的

2014-12-31 佚名 生物谷

一般来讲,改变医生的行医方式是很困难的,近日,一项刊登于国际杂志Vaccine上的研究论文中,来自波士顿大学医学中心的研究人员通过研究表示,将质量改进及激励措施同传统的教育相结合或许可以改善男孩儿和女孩儿的人乳头瘤病毒(HPV)疫苗的接种率,该研究或为持续性改善HPV疫苗的接种率提供帮助。 每年大约有300万美国人寻找治疗HPV相关疾病的疗法,2.7万美国人都患有HPV相关的癌症,而5000多

一般来讲,改变医生的行医方式是很困难的,近日,一项刊登于国际杂志Vaccine上的研究论文中,来自波士顿大学医学中心的研究人员通过研究表示,将质量改进及激励措施同传统的教育相结合或许可以改善男孩儿和女孩儿的人乳头瘤病毒(HPV)疫苗的接种率,该研究或为持续性改善HPV疫苗的接种率提供帮助。

每年大约有300万美国人寻找治疗HPV相关疾病的疗法,2.7万美国人都患有HPV相关的癌症,而5000多人死于相关的疾病;HPV疫苗可以潜在保护个体抵御70%因HPV病毒引发的癌症,但是目前只有不到一半的青少年进行了三种必须疫苗的接种。

这项研究中,研究人员利用一种多组分的性能继续医学教育改善(PI CME)干预措施,其中就包括同医生们进行重复性地接触、重点教育及个体化的反馈等步骤,同时激励医生们完成新的医学专业委员会的认证,这种干预措施在两个联邦合格的医疗中心及六个相同的健康护理网络中心进行,结果研究人员发现,相比对照的健康中心而言,提供干预的中心女孩儿接种疫苗的可能性是前者的2倍,而男孩儿接种疫苗的可能性则为10倍。

近来有研究强调了接种HPV疫苗的重要性,而本文中研究者阐明了提供PI CME干预策略对于改善HPV疫苗接种率的重要性,研究者Rebecca Perkins说道,目前许多美国人遭受着HPV相关癌症的痛苦,而早日接种疫苗则会保护其抵御相关疾病的发生,医生们目前通过对所有的病人进行接种来消除其它疫苗可预防的疾病,而进行HPV疫苗的接种也会帮助有效改善年轻个体的健康状况。

研究者认为,将多组分的持续医学教育同通过电子医学记录获得的常规数据进行结合,或许就可以使得这种干预措施被广泛采纳;他们希望未来可以将这种教育程度更广泛地应用于其它健康系统中来更有效地改善易感个体的HPV的接种率

原始出处:

Perkins RB, Zisblatt L, Legler A, Trucks E, Hanchate A, Gorin SS.Effectiveness of a provider-focused intervention to improve HPV vaccination rates in boys and girls.Vaccine. 2014 Nov 24. pii: S0264-410X(14)01546-1

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1946268, encodeId=6451194626838, content=<a href='/topic/show?id=0e1c9083cc' target=_blank style='color:#2F92EE;'>#HPV疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9083, encryptionId=0e1c9083cc, topicName=HPV疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Mon May 25 11:28:00 CST 2015, time=2015-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078648, encodeId=bb6f20e86482e, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Sun Feb 22 07:28:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773472, encodeId=3b3a1e73472da, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Jun 16 03:28:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257816, encodeId=e508125e81600, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Jan 02 00:28:00 CST 2015, time=2015-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324984, encodeId=11c91324984c8, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Jan 02 00:28:00 CST 2015, time=2015-01-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1946268, encodeId=6451194626838, content=<a href='/topic/show?id=0e1c9083cc' target=_blank style='color:#2F92EE;'>#HPV疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9083, encryptionId=0e1c9083cc, topicName=HPV疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Mon May 25 11:28:00 CST 2015, time=2015-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078648, encodeId=bb6f20e86482e, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Sun Feb 22 07:28:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773472, encodeId=3b3a1e73472da, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Jun 16 03:28:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257816, encodeId=e508125e81600, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Jan 02 00:28:00 CST 2015, time=2015-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324984, encodeId=11c91324984c8, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Jan 02 00:28:00 CST 2015, time=2015-01-02, status=1, ipAttribution=)]
    2015-02-22 gous
  3. [GetPortalCommentsPageByObjectIdResponse(id=1946268, encodeId=6451194626838, content=<a href='/topic/show?id=0e1c9083cc' target=_blank style='color:#2F92EE;'>#HPV疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9083, encryptionId=0e1c9083cc, topicName=HPV疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Mon May 25 11:28:00 CST 2015, time=2015-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078648, encodeId=bb6f20e86482e, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Sun Feb 22 07:28:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773472, encodeId=3b3a1e73472da, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Jun 16 03:28:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257816, encodeId=e508125e81600, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Jan 02 00:28:00 CST 2015, time=2015-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324984, encodeId=11c91324984c8, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Jan 02 00:28:00 CST 2015, time=2015-01-02, status=1, ipAttribution=)]
    2015-06-16 kalseyzl
  4. [GetPortalCommentsPageByObjectIdResponse(id=1946268, encodeId=6451194626838, content=<a href='/topic/show?id=0e1c9083cc' target=_blank style='color:#2F92EE;'>#HPV疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9083, encryptionId=0e1c9083cc, topicName=HPV疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Mon May 25 11:28:00 CST 2015, time=2015-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078648, encodeId=bb6f20e86482e, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Sun Feb 22 07:28:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773472, encodeId=3b3a1e73472da, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Jun 16 03:28:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257816, encodeId=e508125e81600, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Jan 02 00:28:00 CST 2015, time=2015-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324984, encodeId=11c91324984c8, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Jan 02 00:28:00 CST 2015, time=2015-01-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1946268, encodeId=6451194626838, content=<a href='/topic/show?id=0e1c9083cc' target=_blank style='color:#2F92EE;'>#HPV疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9083, encryptionId=0e1c9083cc, topicName=HPV疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=606c2500035, createdName=ms3153534357578991, createdTime=Mon May 25 11:28:00 CST 2015, time=2015-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078648, encodeId=bb6f20e86482e, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Sun Feb 22 07:28:00 CST 2015, time=2015-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773472, encodeId=3b3a1e73472da, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Jun 16 03:28:00 CST 2015, time=2015-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257816, encodeId=e508125e81600, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Jan 02 00:28:00 CST 2015, time=2015-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324984, encodeId=11c91324984c8, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Jan 02 00:28:00 CST 2015, time=2015-01-02, status=1, ipAttribution=)]

相关资讯

WCC 2014:关注性问题:把性健康纳入癌症管理工作的一部分

这次会议的专家小组成员确实是来自五湖四海,他们为证明性健康的重要性和理解人类性生活和亲密行为在有效治疗非性疾病中作用为集聚在一起。在小组会议的开始,Dr Woet Gianotten详细介绍了性生活可带给身体的好处如提高睡眠质量、增加互信和提高关系质量、缓解疼痛以及延长寿命。小组专家认为,除了一些因素是与每个人的生活方式具有内在关联性外,不考虑患者性生活而进行的诊断和治疗最终都

抗艾滋病药物洛匹那韦能有效抑制HPV病毒,防治宫颈癌

一项在肯尼亚进行的临床试验显示,治疗艾滋病的常用药物洛匹那韦对于人乳头瘤病毒(HPV)导致的宫颈病变具有良好疗效,能够防止其发展成宫颈癌。 此间媒体近日报道说,这项试验是肯尼亚肯雅塔国家医院和英国曼彻斯特大学联合进行的。40名因感染HPV而发生宫颈癌前病变的女性参与试验,她们将洛匹那韦作为宫颈栓剂使用,连续用药两周。 试验开始时,40名患者都患有不同程度的宫颈癌前病变,其中23名为高度病变,3个月

包皮环切术可减少HPV负荷量

Nature Reviews Urology近日刊文报道,包皮环切术可以减少高危型人乳头瘤病毒(HPV)的负荷量。 高危型人乳头瘤病毒如HPV16和HPV18可以导致阴茎癌和宫颈癌;男性高病毒负荷量的HPV感染可以增加女性性伴侣病毒感染的机会。以前的研究表明男性包皮环切可以减少高危型HPV感染,但是没有探讨包皮环切对阴茎病毒负荷量的影响。 来自肯尼亚的研究者在2

郎景和:16+18=85,两种HPV病毒导致八成宫颈癌

对于数学运算来说,“16+18=85”显然是错误的,但对于所有女性来说,这个计算式却非常重要。此间提示了三个非常重要的信息,即我国超过85%的宫颈癌都是由“HPV16”和“HPV18”引起的。 宫颈癌是世界第三大常见女性癌症。全球每年有将近50万名女性被诊断为宫颈癌,死亡率高达50%,且主要发生在亚洲。研究证实,99%的宫颈癌病例都是由人乳头状瘤病毒(HPV)导致的。大部分HPV感染都没有症状,能

宫颈癌疫苗:国内为何独缺席

   虽然在很多国家,宫颈癌疫苗已经上市,但在中国,生产宫颈癌疫苗的公司依旧很难获得市场“通行证”。(CFP/图) 八年前,世界上第一支可以预防癌症的疫苗——HPV疫苗上市;七年前,疫苗开始了中国内地的上市之路;现在,在内地,因为新药审评标准存在争议,它依然是被禁止的。 中国每年约有8万女性因宫颈癌去世,约有15万新增病例。而学者研究显示,2006-2012年间,因为9到15岁的女孩未能

The Lancet:宫颈癌HPV筛查优于细胞学检查

尽管敏感性不高,但传统的宫颈癌细胞学检查方法(宫颈癌刮片检查)一直以来都是最成功的癌症筛查方案。在大规模、高质量开展该项检查手段的国家和地区,侵袭性宫颈癌发生率和死亡率呈直线下降趋势。在此前提下,为什么要改变这一检查手段呢? 自从鉴别出人乳头瘤病毒(HPV)是侵袭性宫颈癌的原因,人们开发了HPV DNA检查手段以应对这一疾病。分子学技术在检出2级或3级宫颈上皮内瘤(CIN2或CIN3)病